5.31
0.21 (4.12%)
| Previous Close | 5.10 |
| Open | 5.26 |
| Volume | 1,896,178 |
| Avg. Volume (3M) | 2,962,593 |
| Market Cap | 480,769,024 |
| Price / Earnings (Forward) | 6.43 |
| Price / Sales | 0.330 |
| Price / Book | 1.56 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Profit Margin | -29.43% |
| Operating Margin (TTM) | -3.81% |
| Diluted EPS (TTM) | -8.39 |
| Quarterly Revenue Growth (YOY) | -1.60% |
| Total Debt/Equity (MRQ) | 149.92% |
| Current Ratio (MRQ) | 0.970 |
| Operating Cash Flow (TTM) | 164.20 M |
| Levered Free Cash Flow (TTM) | 310.66 M |
| Return on Assets (TTM) | -1.74% |
| Return on Equity (TTM) | -61.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Fortrea Holdings Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.40% |
| % Held by Institutions | 101.90% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.00 (Baird, 163.65%) | Buy |
| Median | 7.00 (31.83%) | |
| Low | 6.00 (Barclays, 12.99%) | Sell |
| Average | 8.70 (63.84%) | |
| Total | 1 Buy, 3 Hold, 1 Sell | |
| Avg. Price @ Call | 7.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 09 Sep 2025 | 9.50 (78.91%) | Hold | 10.07 |
| Baird | 03 Sep 2025 | 14.00 (163.65%) | Buy | 10.69 |
| 04 Aug 2025 | 9.00 (69.49%) | Buy | 6.42 | |
| Evercore ISI Group | 08 Aug 2025 | 7.00 (31.83%) | Hold | 6.58 |
| 09 Jul 2025 | 5.00 (-5.84%) | Hold | 5.04 | |
| Barclays | 07 Aug 2025 | 6.00 (12.99%) | Sell | 7.24 |
| Mizuho | 11 Jul 2025 | 7.00 (31.83%) | Hold | 5.11 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Sep 2025 | Announcement | Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Aug 2025 | Announcement | Fortrea Reports Second Quarter 2025 Results |
| 05 Aug 2025 | Announcement | Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations |
| 04 Aug 2025 | Announcement | Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
| 16 Jul 2025 | Announcement | Fortrea Announces Date for Second Quarter 2025 Financial Results and Conference Call |
| 24 Jun 2025 | Announcement | Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |